
Medeia Therapeutics Ltd., founded in 2006, is a private biotechnology company dedicated to discover and develop completely new therapeutic approaches for diseases with high unmet medical needs.
Medeia’s focus areas include the discovery , preclinical research and early development of novel therapeutics. Our R&D programs aim at developing therapeutics for life-threatening conditions of the elderly, focusing especially on serious neurological diseases such as Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis and other degenerative diseases. Our R&D pipeline consists of both small molecule and cell-based therapeutic approaches.
Medeia operates under a semi-virtual business model- we outsource all non-core business functions while retaining seamless control over key technology assets, strategic partnerships and financial management with a small core group of highly experienced employees.
Medeia Therapeutics Ltd has been awarded a 0,65 million euro grant from Young Innovative Company (YIC) program financed by Tekes.
Read more...
Medeia Therapeutics receives significant support from Finnish Funding Agency for Technology and Innovation (Tekes)
Read more...
Medeia Therapeutics announces the second financing round led by Inveni Capital
Read more...